|

Lisaftoclax (APG-2575) Clinical Trials

2 actively recruiting trials

Also known as: Induction phase, Maintenance phase

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Ruijin Hospital1
  • Ascentage Pharma Group Inc.1

Indications

  • Cancer2
  • Relapsed/Refractory Acute Myeloid Leukaemia1
  • Mantle Cell Lymphoma (MCL)1
  • Myeloid Malignancy1

Other2 trials

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.